AI assistant
Sending…
Krystal Biotech, Inc. — Director's Dealing 2021
Jul 2, 2021
31006_dirs_2021-07-02_3f41023b-8acb-4e20-9fcc-58c75483d418.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Krystal Biotech, Inc. (KRYS)
CIK: 0001711279
Period of Report: 2021-06-30
Reporting Person: Marantz Jing L. (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-30 | Stock Option (Right to Buy) | $68.0 | A | 6800 | Acquired | 2031-06-30 | Common Stock (6800.0) | Direct |
Footnotes
F1: The options were awarded on June 30, 2021 and vest in equal monthly tranches over a one-year period.
More from Krystal Biotech, Inc.
Declaration of Voting Results & Voting Rights Announcements
2026
May 19
Earnings Release
2026
May 4
Interim / Quarterly Report
2026
May 4
Annual Report
2026
Apr 3
Proxy Solicitation & Information Statement
2026
Apr 3
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4